Blood test guides fight against stubborn lymphoma

NCT ID NCT07021989

Summary

This study is testing a combination of four drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) for adults whose classic Hodgkin lymphoma has returned or not responded to initial treatment. It aims to see if this treatment can achieve a deep remission, measured by both imaging scans and a sensitive blood test that looks for tiny amounts of leftover cancer DNA. The blood test results will help decide if patients need additional, less intensive treatment to try to keep the cancer away.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis

    Davis, California, 95616, United States

  • University of California Irvine

    Irvine, California, 92617, United States

  • University of California San Francisco-Fresno

    Fresno, California, 93701, United States

  • University of California, San Diego

    La Jolla, California, 92093, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Unversity of California, Los Angeles

    Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.